Aphria (NASDAQ: APHA) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its competitors? We will compare Aphria to related companies based on the strength of its dividends, earnings, valuation, profitability, institutional ownership, risk and analyst recommendations.
Insider & Institutional Ownership
11.3% of Aphria shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Aphria and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aphria||$405.96 million||-$63.21 million||-77.50|
|Aphria Competitors||$218.50 million||-$99.79 million||1.73|
Aphria has higher revenue and earnings than its competitors. Aphria is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Aphria and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Aphria has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Aphria’s competitors have a beta of 2.56, suggesting that their average stock price is 156% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Aphria and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aphria currently has a consensus target price of $9.88, indicating a potential upside of 112.37%. As a group, “Medicinals & botanicals” companies have a potential upside of 97.53%. Given Aphria’s stronger consensus rating and higher probable upside, analysts plainly believe Aphria is more favorable than its competitors.
Aphria beats its competitors on 8 of the 13 factors compared.
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.